ATON
AlphaTON Capital Corp. · Financial Services
AlphaTON Capital Corp. · Financial Services
AlphaTON Capital Corp. is the rebranded entity formerly known as Portage Biotech Inc., a clinical-stage immuno-oncology company transitioning into a digital asset treasury model focused on accumulating and staking Toncoin (TON). AlphaTON intends to invest significantly in TON tokens, targeting a Long-Term TON treasury of approximately US $100 million.
Financial Services
Asset Management
4
2002-01-02
0.49

Tortola, British Virgin Islands, March 19, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON), a public technology company dedicated to scaling the Telegram super-app ecosystem, today announced it has entered into a definitive agreement to acquire a 60% controlling interest in GAMEE, a leading mobile gaming platform and wholly owned subsidiary of Animoca Brands. Concurrently, AlphaTON and Animoca Brands have formalized a Strategic Alliance to pursue broader commercial opportunities across blockchain and social gaming.

Washington, DC, USA, March 03, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) and the Midnight Foundation today announced the unveiling of Vera Report, the world's first anonymous reporting platform built on privacy-preserving blockchain technology and confidential compute. Confidential compute means submitted data is technically impossible to access without the permission of the person who provided it.

LISBON, PORTUGAL, March 02, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON), the leading public technology company scaling the Telegram super-app and decentralized AI infrastructure, today announced the appointment of Aleksej Paschenko and Andrei Pfau as Senior Engineers. As AlphaTON accelerates its mission to provide privacy-preserving infrastructure for Telegram's 1 billion monthly active users, these dual hires signal a major leap in technical capability.

Road Town, Tortola, British Virgin Islands, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. ( Nasdaq: ATON ) ("AlphaTON" or the "Company"), the world's leading public technology company scaling the Telegram super-app with an addressable market of one billion monthly active users, today announced a market update on its outstanding shares, warrants, options, and RSUs. As of February 19, 2026, the Company has outstanding: 23,434,588 ordinary shares 1,373,686 ordinary shares issuable upon the exercise of outstanding warrants, with a weighted average exercise price of $11.62 per share; 1,283,931 ordinary shares issuable upon the exercise of outstanding pre-funded warrants from PIPE investment in 2025; 316,111 ordinary shares issuable upon the exercise of outstanding share options under our 2021 Equity Incentive Plan, with a weighted average exercise price of $40.65 per share; and 5,410 ordinary shares issuable upon the vesting of outstanding restricted share units under our 2021 Equity Incentive Plan.

San Juan, Puerto Rico, USA, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Brittany Kaiser, whistleblower, data rights pioneer, and the CEO of AlphaTON Capital (NASDAQ: ATON), joins Mario Nawfal X Space for a live conversation on confidential AI access and why everyone needs to own their digital identity. For the first time, she will reveal the strategy behind AlphaTON's GPU acquisition playbook, the infrastructure powering Cocoon AI (Telegram's AI), and why this Nasdaq listed company is building the future of Privacy-Preserving AI, Confidential Compute, and the rise of Telegram as the world's next great technology super app.

Dover, DE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) ("AlphaTON" or the "Company"), the world's leading public technology company scaling the Telegram super app for an addressable market of over 1 billion monthly active users, today announced the execution of a binding call option agreement with Immunova, LLC ("Immunova"), granting Immunova, or an affiliate, the option to acquire iOx Therapeutics Limited ("iOx"), a wholly owned subsidiary of AlphaTON focused on developing liposomal iNKT agonists. Upon exercise of the option and completion of the acquisition, AlphaTON would be entitled to an upfront cash payment at closing, equity consideration representing 10% of the fully diluted equity of the acquiring entity at the time of exercise, milestone payments potentially exceeding $100 million (payable upon achievement of specified milestones), and single-digit royalties on future net sales, subject to the terms of the definitive documentation.
Levitt Wesley Allen
officer
0 SH @ $0.00
2026-03-18